- Mirabegron (Myrbetriq) and solifenacin (Vesicare) combination therapy is a well‐tolerated and effective treatment for older patients with overactive bladder (OAB).
Why this matters
- OAB symptoms increase with age.
- This study is the first to evaluate long-term tolerability and effectiveness of mirabegron and solifenacin in combination in both young and old patients.
- Researchers analyzed the health records of patients with symptoms of wet OAB who participated in the mirabegron-solifenacin trial (N=1794; age ≥65 years, 614; age ≥75 years, 168).
- Patients were randomly assigned to receive a once‐daily combination of solifenacin succinate 5 mg and mirabegron 50 mg, solifenacin succinate 5 mg, or mirabegron 50 mg.
- Funding: Astellas Pharma Europe B.V.
- Researchers observed slightly higher incidences of treatment‐emergent adverse events (TEAEs) after combination therapy in all age groups.
- The most common TEAE was dry mouth (
- Combination therapy generally resulted in greater improvements in mean number of incontinence episodes per 24 hours, except for patients aged
- The ≥75 years subgroup had a small sample size.
- A placebo group was not included because of treatment length.